BioMedNewsBreaks – Seelos Therapeutics Inc. (NASDAQ: SEEL) Secures $7M in Registered Direct Offering

Seelos Therapeutics (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, has closed a sale of 8,865,000 shares of common stock with certain institutional investors. According to the update, Seelos Therapeutics secured approximately $7 million in gross proceeds, with each of the shares sold at the price of $0.79. The company also agreed to issue unregistered warrants to the investors to purchase up to 6,648,750 shares of common stock in a concurrent private placement. The warrants have an exercise price of $0.84 per share of common stock, exercisable six months from the date of issuance and with an expiration date five years following the initial date of exercise. Roth Capital Partners acted as sole placement agent for the offering.

To view the full press release, visit http://ibn.fm/4UiOq

About Seelos Therapeutics Inc.

Seelos Therapeutics is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (“CNS”) disorders and other rare disorders. The company’s robust portfolio includes several late-stage clinical assets targeting psychiatric and movement disorders, including orphan diseases. Seelos is based in New York, New York. For more information, please visit www.SeelosTherapeutics.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork